Share
The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News in Numbers
Data: News in Numbers
$190m
The amount Roche has agreed to pay upfront to license technology from Arrakis Therapeutics
10%
Cancer Research UK has announced that it will cut funding to its existing grants and institutes by up to 10%
10%
$483m
The US Government has provided $483m of federal funding to Moderna to support the development of a Covid-19 vaccine
26
According to the WHO, there are 26 diseases for which vaccines are available
2 million
The Japanese Government has decided to increase its stockpiles of Avigan® Tablet for up to 2 million people
Data: News in Numbers
$190m
The amount Roche has agreed to pay upfront to license technology from Arrakis Therapeutics
10%
Cancer Research UK has announced that it will cut funding to its existing grants and institutes by up to 10%
$483m
The US Government has provided $483m of federal funding to Moderna to support the development of a Covid-19 vaccine
26
According to the WHO, there are 26 diseases for which vaccines are available
2 million
The Japanese Government has decided to increase its stockpiles of Avigan® Tablet for up to 2 million people
How confident are you that Pharma/Biotech Companies will be able to develop an effective vaccine for COVID-19 within the next 12 months?
Source: Pharmaceutical technology
How concerned are you that the coronavirus outbreak will disrupt the drug supply chain?
Source: Pharmaceutical technology
Approvals
Koselugo (selumetinib)
The US FDA has approved this Neurofibromatosis Type 1 treatment from AstraZeneca and Merck for the treatment of paediatric patients over the age of two who have symptomatic, inoperable plexiform neurofibromatosis.
Source: Pharmaceutical Technology
Jelmyto (mitomycin gel)
The US FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first non-surgical therapy to treat low-grade upper tract urothelial cancer.
Source: UroGen
Stelara (ustekinumab)
NHS Scotland has approved Janssen’s Stelara for the treatment of adult patients with moderately to severely active ulcerative colitis.
Source: Scottish Medicine Consortium
Sevenfact
The US FDA has approved Sevenfact for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.
Source: HEMA Biologics
Go to top
Go to top
Share this article
